Triferic AVNU® (ferric pyrophosphate citrate; Rockwell Medical), an intravenous formulation of Triferic, is now available for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease.
Triferic is an iron maintenance therapy that delivers between 5 to 7mg of iron with every hemodialysis treatment and maintains hemoglobin without increasing ferritin. Whereas Triferic Dialysate requires liquid bicarbonate for administration, Triferic AVNU is designed for direct intravenous infusion, regardless of a dialysis center’s mode of bicarbonate delivery.
“With Triferic AVNU, more patients will have access to the benefits of Triferic as providers will have added flexibility to administer the IV formulation to their patients who may benefit from physiologic iron maintenance therapy to manage their anemia,” said Russell Ellison, MD, MSc, President and Chief Executive Officer of Rockwell Medical.
Triferic AVNU is supplied as 6.75mg of elemental iron (III)/4.5mL in single-dose luer-lock ampules and is available directly through Rockwell Medical and its exclusive distributor, Metro Medical™, a Cardinal Health company.
For more information visit trifericavnu.com.
- Rockwell Medical announces U.S. availability of Triferic® AVNU for replacement of iron and maintenance of hemoglobin in patients on hemodialysis. [press release]. Wixom, MI: Rockwell Medical, Inc.; February 9, 2021.
- Triferic AVNU [package insert]. Wixom, MI: Rockwell Medical, Inc.; 2021.
This article originally appeared on MPR